iProgen and Biorchestra launches research collaboration to explore applications of Antibody Oligo Conjugates to treat diseases with unmet medical needs

Biorchestra and iProgen have been approved for an International Research Grant application (Canada-Korea) to work on the research and development of novel antibody oligo conjugate against a series of diseases for two years. Biorchestra will provide oligo chemistry and therapeutics expertise while iProgen will provide ADC discovery and development expertise.